Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are reasonably well and able to carry out daily activities with little or no limitation (as measured by a standard medical scale called ECOG, scored 0 or 1).
• People with a life expectancy of more than 3 months.
• People who have been confirmed (through tissue or cell testing) to have one of the following advanced cancers: head and neck squamous cell carcinoma, pancreatic adenocarcinoma, non-small cell lung cancer, hormone receptor-positive and HER2-negative breast cancer that has stopped responding to a specific type of prior treatment (CDK4/CDK6 inhibitor), platinum-resistant high-grade ovarian, peritoneal, or fallopian tube cancer, or triple negative breast cancer.
• People whose cancer is advanced, has come back, or has spread, and where surgery or radiotherapy are no longer considered potentially curative, after having received standard treatments.
• People whose blood, liver, and kidney function are at adequate levels.
• People who have at least one tumour that can be safely biopsied (a small tissue sample taken for testing), not including tumours in the bone.

Who may not be able to join:

• People who currently have an active and serious infection.
• People who have persistent nausea or vomiting, a long-term digestive condition, or who have had significant bowel surgery that could prevent the study drug from being properly absorbed.
• People who have cancer that has spread to the brain or spinal cord and is causing symptoms.
• People who have or have previously had another separate cancer.
• People who have previously had an organ transplant or a stem cell transplant from a donor.
• People with moderate or severe heart or blood vessel disease.
• People who have received any cancer treatment within 28 days (or within a shorter window based on how long the drug stays in the body) before the first dose of the study drug.
• People who have taken certain medications that strongly affect how the body processes drugs (known as CYP3A inhibitors or inducers) within 14 days before the first dose of the study drug (confirm with trial site if unsure which medications apply).
• People who have taken certain medications that interact with specific drug transport proteins in the body (P-glycoprotein or BCRP inhibitors or inducers) within 14 days before the first dose of the study drug (confirm with trial site if unsure which medications apply).
• People who have taken certain other medications that use the same drug transport pathways in the body within 14 days before the first dose of the study drug (confirm with trial site if unsure which medications apply).
• People who still have unresolved or unstable serious side effects from previous chemotherapy or radiotherapy.
• People who have had, or are scheduled to have, major surgery within 28 days before the first dose of the study drug.

Important: Always verify eligibility with the trial site directly before applying.